TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03790072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OmnImmune®
Description: infusion of OmnImmune® (expanded gamma delta T lymphocytes)
Study: NCT01089218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral amoxicillin/clavulanate 1g (875/125mg)
Description: oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: control
Description: no intervention with the same procedure of FB
Study: NCT00969488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein diet
Description: INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats).
Study: NCT02403960

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: the patients used probiotic tablets in addition to scaling and root planning

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the patients used placebo tablets in addition to scaling and root planning
Study: NCT02593461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daifert

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Study: NCT02713945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Experimental drug administrated orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for the control group
Study: NCT02242760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 2%
Description: Applied topically twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Applied topically daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Applied topically daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Applied topically twice and once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Applied topically twice and once daily
Study: NCT01421069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Subjects aged \<18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).~Subjects aged greater than or equal to 18 years or \>62 kg will receive etanercept SC at a dose of 50 mg QW.
Study: NCT02491216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
Study: NCT04119401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: doppler-guided hemorrhoidal artery ligation
Description: Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Finger-guided hemorrhoidal artery ligation
Description: Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group
Study: NCT00625014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol 3 mg/day for 8 days
Study: NCT03238352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium oxalate
Description: Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium fluoride
Description: Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral rinse containing 0% KOX and 0 ppm fluoride
Study: NCT03254940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.
Study: NCT00918138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Saxagliptin
Description: Tablets, Oral, 0 mg, once daily, 4 weeks
Study: NCT02217787

Intervention type: DRUG
Group type: OTHER
Intervention: PF-06372865
Description: 7.5 mg as 3 x 2.5 mg tablets single dose
Study: NCT01250197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Description: Ophthalmic Solution
Study: NCT03413293

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of bacterial infections
Description: Cultures
Study: NCT03254940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.
Study: NCT01923649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide 90 mg slow release formulation
Description: Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for somatuline slow release 90 mg
Study: NCT04153929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Solution for Injection
Study: NCT03663634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytochalasin B use in ICSI handling medium
Description: A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
Study: NCT03056586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal pessary
Description: A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
Study: NCT00894101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] FLT
Description: 10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
Study: NCT02885597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juanbi pill
Description: 4g, twice a day, 3month, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Juanbi pill placebo
Description: 4g, twice a day, 3month, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5mg, once a week, 3 month, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 5mg, once a week, 3 month, oral
Study: NCT02729311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired PLIÉ Program
Description: The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
Study: NCT03086837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based intervention
Description: Participants will receive supporting messages through a mobile phone based intervention.
Study: NCT04364425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride
Description: Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine hydrochloride
Description: Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Ultrasound guided injection using 15ml or 12 ml of normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Ultrasound guided injection using 15ml or 12 ml of normal saline
Study: NCT04263077

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: The diamond shape technique, which is a kinesio tape technique, will be used in the lateral epicondyle region. The ends of the kinesiotapes will be applied tension-free without overlapping.

Intervention type: OTHER
Group type: OTHER
Intervention: 50% TENSION GROUP
Description: Kinesiotape will be applied to the lateral epicondyle region with 50% tension.

Intervention type: OTHER
Group type: OTHER
Intervention: 75% TENSION GROUP
Description: Kinesiotape will be applied to the lateral epicondyle region with 75% tension.
Study: NCT02767154

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A colloid Dextran 40 solution for extracorporeal circulation
Description: The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
Study: NCT02729311

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Paired PLIÉ Program
Description: The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
Study: NCT00853619

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Service based decision support intervention
Description: Delivering CDS via services

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service based decision support intervention
Description: Delivering CDS via services
Study: NCT00753623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon
Description: ramelteon (8 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: ramelteon (8 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
Study: NCT01042054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard optimised recovery protocol.
Description: * Epidural analgesia for the first 48 hours postoperatively.~* Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound catheter plus patient-controlled analgesia.
Description: * Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~* Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~* Sham epidural catheter applied to the patient's back for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout.
Study: NCT02987244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: epirubicin (70mg/m2)was administered intravenously on d1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: vindesine (4mg)was administered intravenously on d1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide (100mg) was administered intravenously on d1,2,3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone (60mg/m2)was administered intravenously by oral d1-5.
Study: NCT01502670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FACBC Radiotracer
Description: Test radiotracer uptake in lung nodule
Study: NCT01263444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% / timolol 0.5% Fixed Combination
Study: NCT04263077

Intervention type: OTHER
Group type: OTHER
Intervention: 100% TENSION GROUP
Description: Kinesiotape will be applied to the lateral epicondyle region with 100% tension.
Study: NCT02695901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.12% (PerioGard®)
Description: At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
Study: NCT01263444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Habitual prostaglandin monotherapy
Description: Topical ocular therapy used daily as prescribed
Study: NCT02635685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support tool
Description: Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
Study: NCT02839473

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Castalie water spray

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel Hydrosorb®
Study: NCT01781624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Oral Nutritional Supplement
Description: Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
Study: NCT03504267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Education and Resources
Description: The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
Study: NCT03365336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyherbal formulation
Description: Each Flu Care consist of 350 mg of polyherbal component

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75mg
Description: All the participant has to take 75 mg of oseltamivir for five days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75mg
Description: All the participant has to take 75 mg of oseltamivir for five days.
Study: NCT03907449

Intervention type: DIAGNOSTIC_TEST
Intervention: Preview Rapid Strep A test
Description: Rapid assay for the detection of type A streptococcal infection of the throat.
Study: NCT01749800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GVS
Description: A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GVS
Description: A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
Study: NCT02729311

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist control
Description: After engaging in usual activities for 12 weeks, the Waitlist control group participates in the Paired PLIÉ program.
Study: NCT02695901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle solution of M. alternifolia oil (0.3%).
Description: At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
Study: NCT00993200

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: warfarin pharmacogenetic dosing
Description: Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Usual care warfarin dosing
Study: NCT00795860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss - diet only
Description: Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss plus exercise
Description: Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.